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ABSTRACT 
 
Inter-individual and inter-ethnic variations in drug metabolism are creating an obstacle in 
providing efficient and effective drug treatments especially for drugs with narrow therapeutic 
windows. This thesis is contributes to the understanding of the molecular mechanism of these 
variations.  
Paper I is an introduction to the inter-individual and inter-ethnic differences in CYP2C9 
catalysed drug metabolism. Wide inter-individual differences were observed in the metabolic 
ratio of losartan to E-3174 metabolite even among individuals who were not carrying 
defective alleles CYP2C9*2 and CYP2C9*3. Inter-ethnic variation was observed in the 
metabolism of losartan between CYP2C9 wild type Koreans and Swedes. An allelic variation 
in the intronic region between exon 8 and 9 of CYP2C9, IVS8-109A>T was observed to 
cause a lower CYP2C9 activity in Swedes but not Koreans. 
Paper II studied the combination of age, CYP2C9 genotype, ethnicity, smoking habit, 
weight and sex as a predictor of CYP2C9 metabolic ratio variability. Ethnicity was the 
main significant factor influencing between subject-variability in CYP2C9 enzyme activity. 
Additionally, CYP2C9 genotype and smoking were significant contributors to the variation. 
Grouping the subjects based on their ethnicity, we found that CYP2C9 genotype is a major 
predictor for both Koreans and Swedes (27% and 40% of the variability respectively). The 
smoking effect was non-significant in the Swedes but remains as a factor in the Koreans. 
The reason behind the smoking effect in Koreans is unidentified. 
Paper III investigated the possibility of Behcet’s disease as a CYP2C9 inducer. A Swedish 
ultra-rapid CYP2C9 metaboliser was diagnosed with this disease and this study tested the 
possibility in Turkish healthy subjects to have a lower CYP2C9 activity than Behcet’s 
disease patients. Interestingly, the Behcet’s disease patients were shown to have a 
significantly low CYP2C9 metabolic activity. The factors of genetics, medication and 
inflammation-related biomolecules are suspected to have caused this down-regulation. We 
did not find evidence of CYP2C9 genotype and typical Behcet’s disease medication, 
colchicine having any influence on the observed low CYP2C9 metabolic activity. It is very 
possible that inflammation response agent caused this inhibitory effect on CYP2C9 activity. 
Paper IV investigated the effect of the P450 oxidoreductase (POR)*28 variant on the 
metabolic activity of CYP2C9. We screened all Swedish and Koreans CYP2C9*1/*1 subjects 
for POR* 5, *13 and *28. No subject was found to carry *5 or *13. Interestingly, Swedish 
individuals who carry POR*28 allele were observed to display a 1.40 fold increase in 
CYP2C9 enzyme activity compared to none-POR*28 carriers. We screened the ultra-rapid 
metaboliser for this variant and she was also a carrier of this variant. More studies should be 
done to investigate the effect of other SNPs in POR gene to the metabolic activity of drug 
metabolising enzymes.   
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1 INTRODUCTION 
1.1 A SHORT HISTORY OF PHARMACOGENETICS 
The discovery of the cytochrome P450 was first reported in 1955 [1, 2]. The enzyme was 
described to be able to oxidise xenobiotic compounds and is abundant in the endoplasmic 
reticulum of the liver cells [2]. It was named cytochrome P450 because it had a maximum 
absorption at 450 nm in pig and rat microsomes [3, 4]. Parallel to the discovery of the 
cytochrome P450, advances in pharmacology studies witnessed Kalow and Staron 
characterise serum-cholinesterase deficiency in a subject with succinylcholine apnoea in 1957 
[5] followed by the conceptualisation that inheritance explains many individual differences in 
the efficacy and toxicity of drugs [6]. In his paper, he found that hereditary gene-controlled 
enzymatic factors determine why certain individuals become ‘sick’, whereas others are not 
affected by identical drug exposure. This paper may be one of the first evidence -based 
reports on genetic-based inter-individual variability in drug response.  
 
Friedrich Vogel came up with the word ‘pharmacogenetics’ in 1959 [7]. Working on a book 
at the same time, Werner Kalow published a historically important systematic account of 
pharmacogenetics in 1962. The monograph entitled Pharmacogenetics — Heredity and the 
Response to Drugs recorded genetic variations of significance from numerable hosts, insects, 
bacteria and also humans. These genetic variations were recorded in relations to their 
response to environmental chemicals [8]. Since then, the advances in pharmacogenetics 
studies have been moving forward in positive light. The ultimate creation that revolutionised 
the world of genetic studies, the polymerase chain reaction (PCR) technology came up in a 
very timely manner. Two years after the announcement of the novel method of amplifying 
DNA in 1985, the first nomenclature for the P450 supergene family was announced. From 
then on, studies on the important superfamily of drug metabolising enzymes began to speed 
up. Restriction fragment length polymorphism (RFLP) enables the CYP2D6*3 and *4 to be 
discovered amongst poor debrisoquine metabolisers. The important finding of copy number 
variation in the gene was reported by two groups working together lead on a patient who had 
an extremely high oxidation capacity of antidepressants [9-11]. To date, CYP2D6 is still one 
of the most studied CYP450 enzymes. 
1.2 THE CASE OF A CYP2C9 ULTRA-RAPID METABOLISER  
Fast forward to recent times, a group in Karolinska Institutet [12] reported an interesting case 
of a woman who was an ultra-rapid metaboliser of phenytoin. The patient was a 59 years old 
Caucasian who weighted 50kg. She was previously diagnosed with Behçet’s disease due to 
progressive systemic inflammations among others and was on multiple immunomodulation 
therapies. She later on developed recurrent epilepsy and was prescribed phenytoin. Her 
compliance was questioned as her plasma phenytoin level was barely detected. Given two to 
three times higher dosage (600-700mg daily) than recommended (4-5mg/Kg), this patient still 
did not reach the desirable plasma therapeutic level of between 40-80µmol/L. On two 
separate events, this patient was hospitalised due to CNS toxicity symptoms after being 
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prescribed fluconazole. Both events were similar in that she developed severe adverse 
reaction to phenytoin soon after receiving the CYP2C9 inhibitor. Knowing that CYP2C9 and 
CYP2C19 metabolise phenytoin, the patient was genotyped for defective alleles for both 
genes. She was a non-carrier to any of the known defective alleles. The research group tested 
her with CYP2C9 phenotyping probe drug losartan. She was found to have a very high 
CYP2C9 activity by having the losartan/E-3174 metabolic ratio (MR) of less than 0.13. 
Comparing this patient to the general Swedish healthy volunteers phenotyped for losartan/E-
3174 ratio, she is an extremely fast metabolic outlier (Figure 1). 
This curious case of this patient inspired the beginning of this thesis. CYP2C9 is also a well-
studied metabolic enzyme that is responsible of metabolising up to 13% of clinically 
important drugs [13]. However, all the known defective alleles found in the gene cause a 
lower metabolic activity. It is important to find the molecular reason behind the ultra-rapid 
CYP2C9 variant, if there is any. This case is also the example of an inter-individual variation 
in CYP2C9 catalysed pharmacokinetics. Unlike CYP2D6, there is no established cut-off MR 
between the poor metaboliser (PM), extensive metaboliser (EM) and the ultra-rapid 
metaboliser (UM) in CYP2C9. An inter-ethnic variation in CYP2C9 losartan metabolism was 
also observed.  
 
Figure 1. Histogram showing metabolic ratio (MR) of losartan/E-3174 in 146 Swedish 
healthy subjects and an ultra-rapid metaboliser. Subjects are not on oral contraceptives. The 
MRs are log transformed, ‘URM’ indicates the ultra-rapid metaboliser. MR=1 is indicated as 
an arbitral vertical line.  
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1.3 THE PHARMACOGENETICS OF CYP2C9 
The cytochrome P450 isoenzyme CYP2C9 plays an important role in the metabolism of 
many therapeutically important drugs such as phenytoin [14], S-warfarin [15], tolbutamide 
[16], losartan [17], and non-steroidal anti-inflammatory agents (NSAIDs) [13] in vitro and/or 
in vivo. Inter-individual differences in CYP2C9 metabolic activity have been linked to dosing 
difficulty that might lead to ineffective treatments or worse, toxicity [18]. Factors such as 
genetics, age, stimulatory and inhibitory interactions are the usual cause for the variability of 
drug elimination. 
1.4 DETERMINANTS OF CYP2C9 METABOLIC ACTIVITY 
The need to move from ‘one size fits all’ dosage regiments to a more personalised, tailor-
made type of therapy has long been a dream in the clinical pharmacogenetics world. The 
inter-individual variation in drug response is typically monogenic and inherited traits [19].  
However, some cases of drug metabolism variability can be a result of a more complex 
factor. The genetics influence on the pharmacokinetics and pharmacologic effects of 
medications are determined by how important the impact of the variant allele is to the 
mechanism of action [19]. Although the most of the clinically important genotypes have been 
known, the CYP2C9 still display a very wide inter-individual differences in activity, even 
within individuals who do not carry any of the defective allele. Inter-ethnic differences in 
CYP2C9 allele frequencies among most of the world’s major populations have been well 
described [20-22].  
1.4.1 CYP2C9 genotypes 
The first CYP2C9 single nucleotide polymorphisms (SNPs) identified ware CYP2C9*2 
(Arg144Cys) and CYP2C9*3 (Ile359Leu). These alleles are most commonly present in 
Caucasians and Africans but CYP2C9*2 appear to be absent in Asians [23]. These allelic 
variants encodes for an enzyme with decreased activity in vitro and in vivo as compared with 
the ‘wild type’ allele CYP2C9*1 (Arg144 Ile359) [24-26]. Due to the inter-ethnic variability 
in enzyme activity and the differences in distribution of the two alleles, a number of 
population-based genotyping studies have been conducted to identify other polymorphisms in 
different ethnic groups. These studies gave rise to the findings of among others CYP2C9*4 
(Ile359Thr) that seemed to occur exclusively in Japanese individuals [27], but was absent in 
the Koreans. Also CYP2C9*5 and CYP2C9*6 were found in a small group of African-
Americans [28] and black Africans. To this date, almost 60 different CYP2C9 SNPs have 
been reported (http://www.cypalleles.ki.se/cyp2c9.htm). Not all of these SNPs have a 
clinically significant effect. But those that do were found to cause a decrease in CYP2C9 
activity. So far, there is no SNP in the CYP2C9 gene that is found to increase its activity in 
vivo. 
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1.4.2 Gene-gene interaction 
A well-studied example of gene-gene interaction involving CYP2C9 is on warfarin 
metabolism. Warfarin is catalysed by CYP2C9 [29]. Ironically, individuals of Asian origin 
require a lower warfarin dose despite the low frequency of defective CYP2C9 alleles in 
Asians compared to Caucasians [30]. Warfarin is an anti-coagulant that inhibits vitamin K 
epoxide reductase (VKOR) [31]. VKORC1, a subunit of VKORC gene is the target of 
warfarin [32]. Some genetic variations in the VKORC1 gene were found in warfarin-resistant 
patients [33]. Multiple studies have been done on the dynamics of CYP2C9 and VKORC1 
genotypes in determining warfarin dosage. A study demonstrated that the combination of 
both CYP2C9 and VKORC1 genotype is determinant of warfarin dosage requirements. It was 
shown that although Asians carry less of the defective CYP2C9 gene, they are mostly (80%) 
carriers of VKORC1 -1639 A allele. On the other hand, almost 95% of Caucasians carry the -
1639 G allele. The -1639 G allele was seen to increase the activity of VKORC1 by 44% [34]. 
The difference in frequencies of CYP2C9 defective alleles and the VKORC1 -1639 A>G 
allele was also concluded in a Malaysian study [35]. This group has developed an algorithm 
to account for CYP2C9 and VKORC1 genotypes in relation to warfarin dosage. They also 
calculated that the correlation of age and the genotypes contributes up to 37% of warfarin 
dosage variability. A study on Caucasian subjects found that genotypes of VKORC1 primarily 
and CYP2C9 account for up to 40% of warfarin dose variability [36]. 
Another example of gene variation that directly affects the CYP2C9 enzyme activity is the 
P450 (cytochrome) oxidoreductase (POR). POR plays a role in drug hydroxylation by 
assisting electrons transfer from reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) to the CYP P450 enzymes [37, 38]. An in vitro study was conducted by comparing 
wild type CYP2C9/POR expression to combinations of CYP2C9*2 and CYP2C9*3 with POR 
allelic variations A503V, Q153R, A287P and R457H [39]. Using known CYP2C9 probe 
namely flurbiprofen, diclofenac, and tolbutamide, A503V (POR*28) and Q153R (POR*13) 
resulted in an increase of CYP2C9 activity, and A287P (POR*5) and R457H (POR*2) 
showed a reduced activity compared to wild type POR [39]. However, the effect of the POR 
variant A503V varies from one CYP 450 enzyme to another. For example, de Jonge et al., 
[40] reported an increase of CYP3A5 activity in individuals with the POR*28 allele, while 
Sandee et al. [41] showed that this allele caused a decreased CYP2D6 activity. 
1.4.3 Induction or inhibition by xenobiotics 
Co-administration of drugs can directly or indirectly influence the regulation of CYP2C9. 
Some drugs can act as enzyme inducers, whereas others as inhibitors. Competitive inhibition 
can occur between inhibitor and substrate targeting for the same binding site of an enzyme. 
Non-competitive binding can either cause inhibition or induce the production of the enzyme 
through interaction with the promoter or transcription factor-binding sites. For example, 
fluconazole is a well-known potent inhibitor of CYP2C9 [42] as well as many flavonoids 
[43]. We have observed that fluconazole inhibits phenytion metabolism by CYP2C9 in the 
ultra-rapid metaboliser mentioned earlier. Rifampin, on the other hand was observed to 
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induce the enzyme via activation of the pregene X receptor (PXR) [44]. CYP2C9 is mainly 
regulated by PXR and constitutive androstane receptor (CAR) binding sites. Drugs such as 
fluconazole and other azole antifungals have been shown to inhibit CYP2C9 activity in vitro 
and/or in vivo [45]. Anti-gout drug colchicine was also shown in vitro to cause a lower 
CYP2C9 activity [46]. 
1.4.4 Disease 
Disease is also a determinant of CYP2C9 activity. In most in vitro studies, disease-related 
biomolecules caused a disruption in the regulation of CYP2C9 or any other CYP450 enzymes 
in general. Recently, a study has found CYP2C9 is the direct binding target of inflammation-
associated micro RNA-130 in the gene’s 3’-UTR [47]. The group reported a lower CYP2C9 
activity as an effect of the binding in vitro. Behçet’s disease is a systemic immune disease; 
therefore, it would be very interesting to see the effect of such diseases in vivo. A report on 
mRNA expression of CYP2C9 and CYP2C19 in human hepatocytes showed cytokines IL-6 
and TGF to cause a significant decrease of 30% to 50% in their expression [48]. Besides that, 
several other reports have shown that immune responsive agents are involved in the down 
regulation of CYP2C9.  
1.4.5 Other factors 
Intrinsic-physiologic factors such as age, weight and sex were seen to be weak predictors of 
warfarin dosage determination [49]. Some reports have found that age might have a higher 
priority in the determination of warfarin dosage [50]. Weight is not seen as a significant 
determinant of warfarin metabolism in a few studies [35, 51]. So far, reports on the effect of 
sex on the metabolism of CYP2C9 have been drug-oriented. For example, S-ibuprofen 
metabolism by CYP2C9 was seen to have a sex-related effect [52]. Other reports denied the 
sex-based effect of CYP2C9 [53]. The effects of extrinsic factors such as smoking and diet on 
CYP2C9 activity were also extensively studied but to date, they studies have been very broad 
in spectrum and often inconclusive [54-56]. 
  
  6 
2 AIMS 
The general aim of this study was to further understand the pharmacokinetic variability of 
CYP2C9 catalysed drug metabolism.  
The specific aims of the included studies were: 
Study I: 
To find out whether if there is any genetic polymorphism in CYP2C9 that might cause 
ultra-rapid metabolism. 
To investigate the effect of four intronic SNPs on the metabolism of losartan by 
CYP2C9 in Korean and Swedish healthy subjects. 
Study II: 
To investigate the effect of age, CYP2C9 genotypes, ethnicity, weight, smoking and 
sex on CYP2C9 metabolic activity of Koreans and Swedes. 
Study III: 
To investigate if Behçet’s disease causes ultra-rapid metabolism comparing losartan 
MR in Turkish healthy subjects and Behçet’s disease patients. 
Study IV: 
To observe the impact of the POR*28 genotype on CYP2C9 metabolic activity in 
Korean and Swedish healthy subjects. 
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3 SUBJECTS AND METHODS 
3.1 SUBJECTS 
The study population consists of 148 healthy Swedish volunteers from Karolinska 
University Hospital, Huddinge, Sweden, 146 healthy Korean volunteers from Inha 
University Hospital, Incheon, Korea, 96 Turkish healthy volunteers from Hacettepe 
University Hospital, Ankara, Turkey. The 52 Behçet’s disease (BD) patients and 9 other 
patients who were prescribed with colchicine were recruited from the Department of 
Rheumatology at the Hacettepe University Hospital, Ankara, Turkey. All subjects on oral 
contraceptives (OC) were excluded from the study.  
Some of the healthy Turkish subjects (n=73) used in this study have been published in 2004 
[57]. Together with the 52 BD patients, 23 new healthy subjects were recruited to show that 
there is no significant difference in the losartan metabolic ratios (MR) between the 
previously recruited group of healthy Turkish subjects and the recently recruited group. The 
two groups were than merged to form the 96 healthy Turkish subjects. 
Studies I, II and IV were approved by the local ethics committee at Karolinska Institutet, 
Stockholm, Sweden and Inha University Hospital, Incheon, Korea while Study III was 
approved by the ethics committee at Hacettepe University Hospital, Ankara, Turkey and 
Karolinska Institutet, Stockholm, Sweden. All subjects were informed about the study and 
had given their consent before being recruited. These studies were performed in accordance 
with the Helsinki Declaration and The International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 
Guideline for Good Clinical Practice. 
3.2 GENOMIC DNA 
Genomic DNAs were stored in -20°C.  The DNA samples were diluted to 50 ng/µL before 
they were analysed in the laboratory. Each of the samples was labeled numerically to hide 
the subjects’ identity. 
3.3 CYP2C9 GENOTYPING 
Genotyping for CYP2C9*2 and CYP2C9*3 was done using Taqman assays [26].  
Genotyping for CYP2C9*13 was done using PCR- Restriction Fragment Length 
Polymorphism (RFLP) PspGI [58]. The reference sequence of CYP2C9 was retrieved from 
The National Center for Biotechnology Information (NCBI) website (NCBI Reference 
Sequence: NG_008385.1). Due to a very high similarity of CYP2C9 with other subfamilies 
of CYP2C, very specific polymerase chain reaction (PCR) primers for CYP2C9 are 
required. The primers were first designed based on the reference sequence and the sequence 
of the primers was then aligned back to the reference sequences of CYP2C9, CYP2C19 and 
CYP2C8 using an online software; Kalign (http://www.ebi.ac.uk/Tools/msa/kalign/) 
CYP2C9-specific primers sequences were determined.  Nine sets of primers were designed 
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to amplify specifically exon 1 to exon 9 of CYP2C9, the intron-exons junctions, and ~2.5 
Kbp upstream of the start codon (Paper I).  
Four single nucleotide polymorphisms (SNPs) were screened through all the subjects. SNP 
1 [IVS1+83T>C (rs9332104)] and SNP 4 [IVS8-109A>T (rs1934969)] were screened using 
PCR- RFLP while an allele-specific PCR was carried out to detect SNP 2 [IVS2+73T>C 
(rs9332120)] and SNP 3 [IVS6+95A>G (rs9332174)].  
The exact positions of the target variants were identified and primers were designed based 
on the position of the SNP. First PCR was performed to amplify exons 1, 2, 6 and 8 of 
CYP2C9 by using the sequencing primers (Paper I). Two sets of allele-specific primers 
were designed to specifically match SNP 2 and SNP 3. For SNP 1 and SNP 4, the PCR 
amplicon for exon 2 and 6 were digested with 10U of restriction enzymes HpyCH4IV 
(NEB) and TfiI (NEB) respectively. Initially, a gradient PCR was done to obtain the right 
condition to amplify all the nine CYP2C9 regions. The conditions were described in Paper 
I. 
After an overnight incubation at 37°C (SNP 1) or 4-h incubation at 65°C (SNP 4), the 
digested fragments were separated by 3% agarose gel electrophoresis. In this analysis, the 
completely digested fragments will be a positive variant, partly digested PCR products will 
be heterozygous and the wild-type samples will not be digested. SNPs 2 and 3 products 
were analysed using 2% agarose gel electrophoresis. The gels were pre-stained with 
ethidium bromide.  A 100 bp DNA ladder was used as a reference for determination of the 
sizes of the amplicons.   
3.4 POR GENOTYPING 
Genotyping for POR*5, *13, and *28 alleles was carried out using TaqMan® drug 
metabolism genotyping assay and reagents for allelic discrimination (Applied Biosystems, 
USA). Genotyping was carried out using Quant Studio 12 K Flex Real-Time PCR system 
(Life Technologies Inc). The final volume for each reaction was 10 µl, consisting of 
TaqMan fast advanced master mix (Applied Biosystems, USA), TaqMan 20X drug 
metabolism genotyping assays mix (Applied Biosystems, USA), and genomic DNA. The 
PCR conditions are described in Paper IV. 
3.5 CYP2C9 PHENOTYPING 
CYP2C9 metabolic ratio (MR) analysis was carried out in an earlier study by giving 
subjects losartan 50 mg (Cozaar; Merck, Darmstadt Germany) as a single oral dose [17]. 
Losartan and CYP2C9-specific metabolite E-3174 were measured in urine collected for 8 
hours following drug intake [17]. 
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3.6 STATISTICAL ANALYSIS 
Chi square test was used to compare the observed and expected allele frequencies according 
to the Hardy–Weinberg equilibrium. The MR was determined by dividing the molar 
concentration of losartan/metabolite E-3174. CYP2C9 MR was log-transformed before 
statistical analyses were performed. Data were expressed as median and geometric mean, 
95% CI. Independent t-tests were done to compare log CYP2C9 MR between the two study 
populations. Non-parametric tests were performed to compare the median MR differences 
in Paper I. 
Univariate linear regression analyses were used to identify the individual effect of 
covariates. Predictor variables that resulted in p-values < 0.2 in the univariate were entered 
into a stepwise multivariate regression analysis to identify significant predictors in the final 
model. Statistical analyses were performed using SPSS Statistics (IBM Corporation, USA) 
software, version 20.0. P-values of <0.05 were considered to be statistically significant.  
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4 RESULTS 
4.1 SUBJECTS’ DEMOGRAPHICS 
Table 1 summarises the demographics of all subjects included in Study I to IV. A total of 
146 Korean, 148 Swedish, 96 Turkish healthy subjects, and 52 Turkish Behçet’s disease 
patients were participated. Swedish and Korean subjects were recruited for Study I, II, and 
IV. The healthy and Behçet’s diseased Turkish subjects were recruited for Study III. It was 
observed that most of the BD patients, with 3 individuals in exception, were on anti-gout 
medication colchicine. Nine other patients with various inflammation-related illnesses (three 
with familial Mediterranean fever (FMF), two with BD, two with arthritis, one with 
osteoarthritis and one with oral aphthous lesions) were also recruited for Study III 
(demographics unavailable). Individuals who were on oral contraceptive (OC) were excluded 
from all of the studies due to its inhibitory effect on CYP2C9 enzyme activity [26]. 
 
Table 1. Subjects’ demographics according to ethnicity. na; data unavailable 
 
Healthy subjects Turkish Behçet’s 
Patients 
(Study III) 
Koreans 
(Study I, II, IV) 
Swedes 
(Study I, II, IV) 
Turks 
(Study III) 
Sex:      
   Female  72 63 47 24 
   Male  74 85 49 28 
Mean age in 
years (range) 
24.9 
(20-46) 
30.5 
(19-60) 
32.7 
(26-47) 
41.5 
(29-73) 
Weight in kg 
(range) 
62.1 
(38-94) 
71.8 
(50-109) 
72.2 
(56-95) 
72.6 
(50-96) 
Smoking  27 29 na na 
 
4.2 CYP2C9 GENOTYPES 
Genotypes of the subjects in this study were at Hardy-Weinberg's equilibrium for all alleles. 
The CYP2C9 gene of an ultra-rapid metaboliser (MR <0.13) [12] and three other control 
subjects who have normal CYP2C9 metabolism (MR=1) were sequenced. No SNPs were 
detected in the ultra-rapid metaboliser but the controls were identified with four SNPs; SNP 
1: IVS1+83T>C, SNP 2: IVS2+73T>C, SNP 3: IVS6+95A>G and SNP 4: IVS8-109A>T 
(Paper I). All the study subjects were genotyped for CYP2C9*2 (C430T), *3 (A1075C) and 
four additional synonymous SNPs detected from the mentioned earlier controls. The Koreans 
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were screened for an additional genotype, CYP2C9*13. One Korean subject was found to 
carry CYP2C9*13, a CYP2C9-defective variant among Asian individuals (Paper II). 
The CYP2C9 genotype frequencies of the Korean and Swedish subjects are shown in Paper 
II. It was observed that there are differences in the frequency of the allelic variations between 
Koreans and Swedes. Most of the Koreans were CYP2C9*1/*1 (88%) whereas only 59% of 
Swedes carried the wild type allele (Fisher's test, P<0.0001). The CYP2C9*2 allele was not 
detected in the Koreans but occurred at a frequency of 0.11 in the Swedish population. Paper 
III shows that the genotype frequencies for the Turkish healthy subjects and Behçet’s disease 
patients are statistically similar (Fisher's test, P=0.14). 
Paper I discusses the differences in CYP2C9 enzyme activity between Korean and Swedish 
healthy subjects who were non-carriers (denoted as CYP2C9*1/*1) for defective alleles 
CYP2C9*2 and/or *3. The effect of genetic polymorphisms on CYP2C9 metabolic activity 
was tested by screening the four new SNPs against the CYP2C9*1/*1 subjects. The result 
showed a significant difference in the frequency distributions of the polymorphic alleles 
between the Koreans and Swedes. Variants IVS1+83T>C, IVS2+73T>C, and IVS6+95A>G 
were significantly lower in Koreans (Fisher's test, P<0.0001) but not IVS8-109A>T. On the 
other hand, the genotype frequency of CYP2C9*2, *3, and the four synonymous SNPs was 
not significantly different between the Swedes and Turks.  
4.3 POR GENOTYPE 
The distribution of the POR*28 allele was in accordance to Hardy-Weinberg equilibrium in 
both Koreans and Swedes. Observation from Study IV showed that POR*5 and *13 were 
absent in both study populations. There was a difference in the distribution of the POR*28 
allele between the Koreans (43%) and Swedes (30%) (Fisher’s test, p=0.04). Table 2 shows 
the genotype and allelic frequency of POR*28 in Swedes and Koreans. Overall, the 
frequency of subjects carrying the POR*28 allele was 65% in Koreans and 49% in Swedes. 
The same trend was seen among the CYP2C9*1/*1 subjects that were used for Study IV, 
where the POR*28 allele frequency was higher in Koreans (43%) than the Swedes (29%). 
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Table 2. CYP2C9 and POR genotypes for all subjects. The Turkish subjects were not 
genotyped for POR*5, *13 and *28. No POR*5 or *13 variant was detected in any Korean or 
Swedish subjects. na; not available 
Genotype Healthy subjects N (%) Turkish Behçet’s 
disease patients 
N (%) Koreans Swedes Turks 
CYP2C9 
*1/*1 128 (87.7) 87 (58.8) 51 (70.8) 31 (59.6) 
*1/*2 0 24 (16.2) 10 (13.8) 12 (23.1) 
*1/*3 17 (11.6) 29 (19.5) 9 (12.5) 8 (15.4) 
*1/*13 1 (0.7) na na na 
*2/*2 0 2 (1.4) 1 (1.4) 0 
*2/*3 0 4 (2.7) 1 (1.4) 1 (1.9) 
*3/*3 0 2 (1.4) 1(1.4) 0 
IVS1+83  
TT 
TC 
CC 
 
142 (98.6) 
2 (1.4) 
0 
 
82 (56.2) 
62 (42.5) 
2 (1.3) 
 
53 (72.6) 
17 (23.3) 
3 (4.1) 
 
43 (82.7) 
8 (15.4) 
1 (1.9) 
IVS2+73  
TT 
TC 
CC 
 
142 (98.6) 
2 (1.4) 
0 
 
95 (65.1) 
44 (31.1) 
7 (4.8) 
 
53 (72.6) 
16 (21.9) 
4 (5.5) 
 
49 (94.2) 
3 (5.8) 
0 
IVS6+95  
AA 
AG 
GG 
 
142 (98.6) 
2 (1.4) 
0 
 
88 (60.3) 
56 (38.4) 
2 (1.4) 
 
53 (72.6) 
17 (23.3) 
3 (4.1) 
 
42 (80.7) 
7 (13.5) 
3 (5.7) 
IVS8-109  
AA 
AT 
TT 
 
62 (43.1) 
62 (43.1) 
20 (13.8) 
 
74 (50.7) 
54 (37.0) 
18 (12.3) 
 
44 (60.3) 
22 (30.1) 
7 (9.6) 
 
28 (53.8) 
20 (38.5) 
4 (7.7) 
POR     
*28 CC 45 (35.0) 45 (50.7) na na 
*28 CT 58 (43.6) 44 (43.1) na na 
*28 TT 30 (21.4) 6 (9.2) na na 
Total 133 (100) 95 (100)   
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4.4 GENETIC LINKAGE IN CYP2C9 
Figure 2 shows the linkage association among the CYP2C9 SNPs studied. There is a 
complete linkage predicted in the Koreans for IVS1+83T, IVS2+73T, and IVS6+95A. This 
result is almost predictable because the mutated alleles are very rare in this population. The 
Koreans also showed high D’ value (0.64) between two wild type alleles in Block 2. There is 
a low degree of linkage observed between IVS1+83T with IVS2+73T (D’=0.37) and 
IVS1+83T with IVS6+95A (D’=0.54) in the Swedes indicating none of the other SNPs in 
Koreans or Swedes are in linkage to one another. The majority of Turkish healthy subjects 
were wild type (D’=0.73). The second most common haplotype for the Turks carried the 
mutated allele IVS6+95G (9%). The same observation was made in the Behçet’s disease 
group.  
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Figure 2. The linkage disequilibrium (LD) among the studied CYP2C9 SNPs. This figure 
predicts the linkage between the polymorphisms and the resulting LD blocks at the CYP2C9 
locus. LD block size is given as horizontal bars as calculated by Haploview [59].The LD 
blocks drawn below represent the LD blocks between the SNPs. Dark red boxes without a 
value denote a D'-value of 1.00; light blue boxes without a value denote a not determinable 
value. Numbers denote the 100-fold of the respective D'-values. The higher the value, the 
darker the fill colour of the boxes and the higher the LD. 
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4.5 THE EFFECT OF CYP2C9 GENOTYPES ON CYP2C9 PHENOTYPE 
The metabolic ratio (MR) of losartan to its CYP2C9-specific metabolite E-3174 was 
measured in all subjects. There is a similarity in the MR of Swedes and Turks (Figure 2). 
However, Koreans display a significantly different MR profile, where they were observed to 
have a lower MR, indicating a more rapid metabolism of losartan to E-3174 by CYP2C9 
compared to Swedes (p<0.001). After dividing the subjects into their genotype groups, 
significant differences were still observed between Koreans and Swedes in both the 
CYP2C9*1/*1 (P<0.001) and CYP2C9 *1/*3 groups (P=0.001) (Paper II, Fig 2).  
There was also a significant difference in CYP2C9 enzyme activity observed between the 
Turkish healthy subjects and the BD patients (P=0.002).  In contrast to the ultra-rapid 
metaboliser who also suffered from BD, the subjects who were in the BD patients groups 
showed a higher MR compared to the healthy subjects (Paper III).   
4.6 THE EFFECT OF POR GENOTYPE ON CYP2C9 PHENOTYPE 
Considering subjects with CYP2C9*1/*1 genotypes only, the CYP2C9 MR was significantly 
lower in individuals who carried the POR*28 allele among Swedes (P=0.02) but not Koreans 
(P=0.68). The geometric mean of MR between the subjects who carried the allele POR*28 
and subjects without the allele was significantly different in Swedes (0.64 vs 0.89, P=0.002). 
However no significant difference in CYP2C9 enzyme activity between the different 
POR*28 genotype groups was observed in the Korean population (0.56 vs 0.55, P=0.68) 
(Paper IV, Table 2). 
The effect of POR*28 genotype on CYP2C9 MR among Koreans was tested by excluding 
smoking individuals. No significant difference in CYP2C9 MR between POR wild-type and 
POR*28 carrier was found among non-smokers (t-test, p=0.97). A similar observation was 
found in smokers (t-test, p=0.38). Result signified there is no effect of POR*28 genotype on 
CYP2C9 enzyme activity in Korean subjects regardless of smoking status. 
Multiple linear regression analysis showed that the effect of the POR*28 genotype 
contributes up to 8% (step 1, ANOVA p=0.02) of variation in Swedes. Together with sex, the 
variables are up to 11% (step 2, ANOVA p=0.03) responsible for CYP2C9 activity variation 
in this group. 
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Figure 3. Histogram showing metabolic ratio (MR) of losartan/E-3174 according to 
ethnicity. The MR are log transformed, ‘*’ indicates the median MR and ‘URM’ indicates the 
ultra-rapid metaboliser. MR=1 is indicated as an arbitral vertical line. 
 
 
 
P < 0.001 
URM 
   17 
4.7 THE EFFECT OF BEHÇET’S DISEASE ON CYP2C9 CATALYSED 
METABOLISM 
The key differences between the Turkish healthy subjects and the BD patients were the 
medication they took and the lack pathophysiology of the disease in the healthy subjects. The 
colchicine dosages received by the BD patients ranged from 1 to 4 mg/day, with 29 patients 
receiving 3 mg/day, 11 receiving 2 mg/day, 4 receiving 1 mg/day and 2 patients receiving 4 
mg/day. The list of their concurrent medications with median dosage is shown in Appendix 1, 
in Paper III. Among these drugs, one subject was found to be on CYP2C9 inducer 
carbamazepine at 600 mg daily (with genotype CYP2C9*1/*2 and losartan MR 2.0), and 
several were on CYP2C9 substrate/inhibitors: warfarin with median dosage of 5 mg daily 
(eight individuals), omeprazole 20 mg daily (three individuals) and sertraline 50 mg daily 
(one individual). The patient who was on warfarin was genotyped as CYP2C9*1/*2 and the 
patient with sertraline had the MR of 1.92, which was close to the median MR of the BD 
patients groups (1.74). The three patients on omeprazole showed no significant impact on 
their CYP2C9 activity (MR= 0.91-1.64). Among the eight individuals on warfarin, three were 
CYP2C9*1/*1 and they had the MR of 0.98 to 1.26, which are lower than the median for the 
group but not lower than the healthy subjects’ (MR=0.80). 
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Figure 4. Comparison of losartan/E-3174 ratio between the Behçet’s disease patients and 
Turkish healthy subjects. The three patients in red represent patients who were not on 
colchicine treatment. MR: metabolic ratio. MR=1 is indicated as an arbitral vertical line. 
Numbers represents the median MR of each group. *;Swedish ultra-rapid metaboliser with 
Behçet’s disease. MR < 0.13 [12]. Figure reproduced with permission.  
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4.8 THE EFFECT OF COLCHICINE TREATMENT ON CYP2C9 CATALYSED 
METABOLISM 
In nine patients about to be prescribed with colchicine, losartan MR was measured before 
starting treatment and again after 2 weeks of colchicine treatment. The dosages of colchicine 
given to the nine patients (four patients received 3 mg/day, three patients received 2 mg/day 
and two patients received 1 mg/day) were very similar to those given to our large group of 
BD patients. There was no difference in geometric mean MR before (3.00) compared to 2.80 
during colchicine (P=0.89, 90 % CI: 0.38–3.02) (Figure 5). Three patients did not show any 
change in their MR, three had lower MR during colchicine treatment and three had higher 
MR. 
 
 
Turkish patients 
 
Figure 5. Metabolic ratio before and during colchicine in inflammation- related diseased 
patients. MR; metabolic ratio and MR=1 is indicated as an arbitral vertical line 
 
 
 
  20 
4.9 THE EFFECT OF ENVIRONMENT ON CYP2C9 CATALYSED METABOLISM 
In addition to ethnicity, CYP2C9 genotype is a strong determinant for CYP2C9 metabolic 
activity in this study group. There is however, a fraction of external factors that also plays an 
important role in determining CYP2C9 metabolic activity. In Paper II, the effects of external 
factors such as age, sex, weight, ethnicity, and smoking were evaluated together with 
CYP2C9 genotype to determine their significance on CYP2C9 metabolism. Univariate 
analysis showed that ethnicity (P<0.0001), CYP2C9 genotype (P<0.0001), and smoking 
(P=0.009) are the main predictors of the differences in CYP2C9 MR. Stepwise multiple 
regression analysis shows that 50% of the CYP2C9 MR variation is due to the three 
mentioned factors. Among the three, CYP2C9 genotype is, however, the most important 
predictor accounting for 40% of the variation factor.   
After grouping the subjects according to their ethnicity, univariate analysis indicated CYP2C9 
genotype as the main contributor for variations in CYP2C9 metabolic activity in both ethnic 
groups (P<0.0001 in both groups). Interestingly, smoking was a second significant predictor 
to influence CYP2C9 metabolic activity in Koreans (P=0.003). Multivariate regression 
analysis showed that CYP2C9 is the main factor contributing to variation in CYP2C9 MR in 
both populations (26.6% in Koreans and 39.6% in Swedes). Adding smoking to the CYP2C9 
genotype effect explaines 31% between-subject variability in CYP2C9 MR among Koreans. 
None of the tested potential non-genetic predictors including body weight and age had a 
significant impact on the CYP2C9 phenotype in Swedes.  
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5 DISCUSSION 
This thesis was initially formulated with the aim of understanding the effect of several 
biological and molecular factors that affect the human CYP2C9 enzyme metabolic activity. 
These variants are genetics, environmental factors such as age, weight, sex, and lifestyle 
(smoking), as well as geographical factors (ethnic and dietary).  
The true birth of this study was in 2010, when an ultra-rapid metaboliser of phenytoin and 
losartan, both CYP2C9 substrates was discovered. She also suffered from Behçet’s disease 
[12]. The patient was an extreme outlier compared to the 148 healthy Swedish subjects 
(URM in Figure 1). This group of Swedish healthy subjects was already shown to portray 
some interesting features. First; although after they were classified according to their 
genotype, there was still a wide inter-individual difference in their CYP2C9 MR. Second; 
the median CYP2C9 MR of healthy Swedes was significantly different from the median 
CYP2C9 MR of the Korean healthy subjects. The Koreans had a lower CYP2C9 MR 
compared to Swedes. These observations led to the hypothesis that there might be an 
unknown molecular or environmental factor contributing to a lower CYP2C9 MR (higher 
CYP2C9 metabolic activity).  
To test the hypothesis, direct capillary sequencing on the CYP2C9 gene of the ultra-rapid 
metaboliser and three other Swedish ”control” normal metabolisers was carried out. As 
discussed in Paper I, the three controls were found to carry 4 synonymous SNPs but no 
allelic variation was found of the ultra-rapid metaboliser. This discovery led to a new 
hypothesis that the SNPs detected might be causing the controls and the rest of the Swedish 
population to have a lower CYP2C9 metabolism. Factors that might contribute to CYP2C9 
metabolic variabilities were observed in Study II. The possibility of Behçet’s disease being 
an inducer to a lower MR was investigated in Study III. Finally, in Study IV, the external 
factor that plays a role in the redox of CYP2C9, the POR gene variant *28, and its effect on 
CYP2C9 metabolic activity was studied. 
5.1 THE EFFECT OF GENETICS ON CYP2C9 CATALYSED METABOLISM 
In general, Swedes were observed to have a lower CYP2C9 activity compared to Koreans. 
CYP2C9 genotyping showed that there is a relation between alleles *2 and *3 in Swedes 
and *3 and *13 in Koreans to lower CYP2C9 metabolic activity. However, comparing 
Koreans and Swedes with CYP2C9*1/*3 genotypes, Koreans are still observed to display a 
significantly higher CYP2C9 activity. To date, it has been well known that almost all 
known functioning CYP2C9 allelic variations are responsible for defective enzymes. 
Having just one of the functional variant alleles will result in a lower CYP2C9 activity. 
Population studies have reported that some of these CYP2C9 allelic variations are ethnicity-
specific, for example, in this study, no CYP2C9*2 was detected in the Koreans and *2 and 
*3 were not detected in the Canadian Inuit population [60]. The Inuits are thought to be of 
Asian ancestry and showed a geographical aspect of genetic variability in not carrying the 
CYP2C9*3 allele. CYP2C9*2 and *3 alleles occur at almost the same frequencies in 
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Swedish and Turkish subjects in this study. CYP2C9*5 and CYP2C9*6, for example, were 
found to be inherited by a small group of African-Americans [61]. CYP2C9*13 was 
detected in one of the Korean subjects in Study II and the allele was also detected in low 
frequency in Japanese [62] and in Koreans [58] but it occurred up to 2% in the Chinese 
population [43].  
A higher frequency of CYP2C9 defective variant alleles occurred in the Swedes and Turks 
compared to the Koreans (Table 2). Several other studies have also reported that a higher 
number of defective CYP2C9 alleles in Caucasian individuals [63, 64]. This finding could 
explain the overall lower CYP2C9 activity seen in the Caucasian population compared to 
Asians. Referring to Figure 1, the Swedes and Turks have a broader distribution curve, 
suggesting that there are possibly more contributing genetic factors to the metabolic rate 
diversity. Further genotype and phenotype cross-match studies should be done to 
completely understand the actual effect of these allelic variations.  
Although copy number variation (CNV) has been extensively reported for CYP2D6, there 
might not have been any significant finding on any clinically important CNV on CYP2C9 
and CYP2C19. A pre-screening done on the genome of the ultra-rapid metaboliser has 
shown that she did not carry any CNV in and around her CYP2C9 and CYP2C19 genetic 
region. Therefore, CNV is not the explanation of the ultra-rapid metabolism.  
Papers I and III highlighted that there is a high number of Swedish and Turkish 
IVS1+83T>C, IVS2+73T>C, and IVS6+95A>G allele carriers respectively. The Swedish 
and Turkish healthy subjects showed that there is no linkage observed among the studied 
SNPs. In the Koreans, however, IVS1+83T>C, IVS2+73T>C, and IVS6+95A>G are linked 
to each other. However, there are only two individuals who carry the polymorphisms. A 
Japanese population based study also reported the three SNPs as haplotype *1h that is also 
linked to IVS1+83T>C [65]. In this population, 4 individuals out of 263 subjects carried the 
haplotype and 2 other individuals had an additional SNP in the haplotypes. Allele IVS8 
+109 T>A on the other hand occurs in a homogeneously high frequency in all populations. 
The observed effect of IVS8 +109 T>A on the Swedish healthy subjects was probably due 
to its linkage to another important polymorphism that is not yet determined. This SNP also 
does not have any effect on the CYP2C9 activity of the Turkish healthy subjects and 
Behçet’s disease patients (Paper III). 
POR*28 is known to increase CYP2C9 catalysed drug metabolism in vitro [39]. Study IV 
shows that the Swedish individuals carrying the mutated allele have a significantly lower 
CYP2C9 MR mean compared to the Swedish individuals without. Interestingly, the ultra-
rapid metaboliser was also genotyped as a POR*28 carrier. Of course, this is probably just a 
small contributing factor to her extreme CYP2C9 metabolic rate. This finding is also in 
accordance to the earlier in vitro report showing that POR*28 causes an increase of 
CYP2C9 activity [39]. Interestingly, in Koreans, where there are more individuals carrying 
the POR*28 allele, the statistical analysis showed no effect of the *28 allele on CYP2C9 
MR in this population. Looking from another perspective, the overall CYP2C9 MR of 
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Koreans is significantly lower compared to Swedes, which supports that the SNP is 
somehow linked to a lower CYP2C9 MR. There are probably more than one allelic 
variation in the POR gene that might be responsible to this difference. For example, SNPs 
366+89C>T and 1248+20G>A in POR were found to be occurring at a frequency of 30% in 
Caucasian liver samples [66]. The combinations of these allelic variations and their 
frequencies in each ethnic population would have an influence on the metabolic activity of 
an enzyme. Lack of POR*5 and *13 alleles in the healthy subjects is expected as the two 
alleles are very common in individuals with congenital malformations [39].  
Gene-gene interaction, in this case the combination of CYP2C9 and POR genotypes 
affecting CYP2C9 activity is very important in understanding drug metabolism. A very 
classic example is the effect of CYP2C9 interaction with VKORC1 that affects warfarin 
dosing. In warfarin metabolism, CYP2C9 plays a role in the metabolism of the enantiomer 
S-warfarin and the pharmacodynamics of warfarin is controlled by its target, vitamin K 
epoxide reductase (VKORC1). A large cohort study has found that CYP2C9, VKORC1, age, 
sex, and drug interactions explained 59% of warfarin dose variability in European subjects 
[67]. Meanwhile a study in Malaysia found that a combination of age and CYP2C9*3 and 
VKORC1 genotypes accounts for 37% of the variability [35].   
5.2 THE EFFECT OF BEHÇET’S DISEASE ON CYP2C9 CATALYSED 
METABOLISM 
The ultra-rapid metaboliser was on phenytoin for her epilepsy, but she also was being 
treated for Bechet’s disease. The possibility of the disease being a factor that causes an 
inhibition or induction is tested in Study III. The significant difference of geometric mean 
of MR between the Turkish healthy subjects and the Behçet’s disease patiets showed that 
the disease does not increase CYP2C9 metabolic activity. In fact, the disease seems to be 
causing a lower CYP2C9 activity (higher MR). The three factors that might be causing this 
down-regulation of CYP2C9 are: genetics, medications and the disease itself. 
Genetics was ruled out in Study III because no significant difference was found in the 
frequency of any of the CYP2C9 allele between the two Turkish groups. The two remaining 
factors are very likely to have an inhibiting effect on CYP2C9 metabolism. Behçet’s 
disease is an inflammatory syndrome. Recent studies have shown that some inflammation 
response agents were responsible to down-regulate CYP2C9. For example, inflammation 
response agents IL-6 and TGF were found to be responsible to down regulate CYP2C9 
[48]. Additionally, very recently, a group in Germany found that microRNA miR-130 
which is associated to inflammation was reported to directly affect CYP2C9 regulation. The 
study was done by inserting the 3’-UTR of CYP2C9 gene to the firefly gene of a plasmid. 
Luciferase activity in HuH7 cells was measured and the binding of miR-130 to the UTR 
putative binding sites inhibited the expression of CYP2C9 [47]. This study directly 
supports the observation of CYP2C9 having lower activity in the Behçet’s disease group. 
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5.3 THE EFFECT OF DRUGS ON CYP2C9 CATALYSED METABOLISM 
Studies have shown that drugs not only are metabolised by CYP enzymes, they also 
influence the induction and inhibition of these catalysts. In the example of the ultra-rapid 
metaboliser, fluconazole that was prescribed to her inhibited CYP2C9 metabolic activity 
and almost completely stopped the metabolism of phenytoin. In Study III, the effect of 
colchicine on CYP2C9 was discussed. All except three of the Behçet’s disease patients 
were on colchicine, which led us to test nine inflammation-related disease patients with 
losartan before and again during colchicine treatment. Results from the nine patients 
showed that colchicine given over two weeks does not have any significant effect on 
CYP2C9 metabolism.  
Some of the studied Behçet’s diseased patients were on medications known to induce 
CYP2C9 activity, for example carbamazepine, and CYP2C9 substrate/inhibitors: warfarin, 
omeprazole, and sertraline. However, overall, they are within the normal distribution curve 
of the Behçet’s disease group and still portray a lower CYP2C9 metabolic activity 
compared to the healthy Turkish subjects. 
5.4 THE EFFECT OF OTHER ENVIRONMENTAL FACTORS ON CYP2C9 
CATALYSED METABOLISM 
Paper II explores the effect of other factors that might have an effect on CYP2C9 
metabolic activity along with genetics in Koreans and Swedes. Estimation by regression 
analysis shows CYP2C9 genotype to have different impact on determining the metabolism 
by CYP2C9 enzyme. Another factor that is known to have an effect on the metabolic 
activity is oral contraceptives [26]. Therefore, in all of our study, individuals on OC were 
excluded.  
In Study II, besides genetics, we tested the effects of ethnicity, age, sex, weight and 
smoking habits on CYP2C9 enzyme activity. Preliminary univariate analysis pointed out 
that genetics, ethnicity, and smoking are the most likely factors determining inter-individual 
CYP2C9 MR differences. The effect of ethnicity was already seen and reported in Study I 
and by comparing the geometric mean of the CYP2C9 MR between both populations. 
Separating the subjects according to their ethnicity, the effect of CYP2C9 genotypes was 
reported in Paper II by comparing the subjects’ MR (Paper II, Figure 2).  
The effect of smoking was not significant in the Swedes but observed in the Koreans. 
Smoking has been known to affect CYP1A2 activity through aryl hydrocarbon receptor 
(AhR) activation by polycyclic aromatic hydrocarbon (PAH) [68, 69]. However, the effect 
of smoking on CYP2C9 should not be excluded. For example, the effect of smoking on 
CYP3A4 was found in a study to be due to the binding of PAH from cigarette smoke to 
common CYP2C9 receptor, the pregnane-X-receptor (PXR) [70]. However, there are a few 
inconsistent findings regarding the effects of smoking on the CYP2C9 enzymes. A study 
found significantly induced CYP2C9 activity in bronchial biopsies of smokers compared to 
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non-smokers [56]. In contrast, the metabolism of warfarin by CYP2C9 of cigarette smokers 
is not significantly different from non-smokers [55]. 
The difference in the CYP2C9 MR between the Koreans and Swedes is mostly due to their 
differences in CYP2C9 genotypes (40% in Swedes and 27% in Koreans). The evidence of 
POR*28 allele having an effect on the activity of this enzyme was seen in Study IV. But 
there are other un-identified genetic, epigenetic, or environmental factors that contribute to 
the variability of CYP2C9 activity. The effect of the interactions between these known and 
yet-to-be-identified factors on CYP2C9 activity would be intersting to observe in the future.  
Diet for example, is an interesting factor because it is not only directly linked to genetic 
build-up, but it is a social-behavioral issue and it is very subjective to an individual’s 
culture background and life-style. Koreans, for example have a different diet than Swedes. 
The Koreans’ staple food contains soy products, meat, and rice. They are also more likely 
to eat spicy food that may contribute to a different metabolic capacity than the Swedes who 
mainly consumes dairy, eggs and wheat products. Diet is unique to every individual and it 
consists of mixtures of compounds that would interact with the hepatic cytochromes just 
like drugs. cranberries, garlic, ginkgo, and St. John's wort were found to have inhibition 
properties towards CYP2C9 activity [71]. Additionally, Korean researchers reported an 
induced CYP3A4 expression in vitro and in vivo by human PXR and CCAAT-enhancer-
binding proteins beta (C/EBPb) from capsaicin, a type of principal pungent ingredient in hot 
red and chili peppers [54]. 
The contributor to the variation of CYP2C9 metabolic activity is mainly genetics. However, 
other factors such as oral contraceptives and anti-fungal medications, and comorbidities are 
very important to account for. This study has found that the genotypes of CYP2C9 and POR 
genes are important to determine the initial metabolic activity of the CYP2C9 enzyme. 
Disease, such as inflammation-related illness may significantly reduce the activity of this 
enzyme and therefore might interfere with the effectiveness of treatments. Other factors 
such as diet, alcohol consumption and smoking although the mechanism of interactions is 
complex and difficult to understand would also be considered as a variation factor.  
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5.5 FUTURE WORK 
Although there are maybe more questions raised at the moment on the impact of 
pharmacogenetics in shaping the future of personalised medicine, there are numerous studies 
being done currently in order to answer them. An interesting question raised from this study 
is the size of impact POR genotype has on the CYP2C9 activity, and whether the ultra-rapid 
metaboliser had a unique mutation on her POR gene that caused the high CYP2C9 activity. It 
would be worthwhile to fully understand the molecular reason to the high CYP2C9 activity, 
and if it could be controlled. Therefore, it would be of a great advantage to be able to 
sequence the ultra-rapid metaboliser’s POR gene and test the functionallity of any non-
synonymous mutation found. Additionally, some POR genetic variations were also reported 
to be affecting other CYP 450 enzymes; looking into the effect of POR allelic variation onto 
other metabolic enzymes while also cross-checking the effects among different ethnicities 
would be a natural path to follow. 
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6 SUMMARY 
Based on the observation of ultra-rapid metaboliser of phenytoin, we designed a study that 
investigated for any molecular or other potential contributing factors behind the observed 
inter-individual variations in CYP2C9 metabolism using losartan as a probe. Realizing that 
there is also an inter-ethnic difference in CYP2C9 metabolism, we further investigated for 
any contributing factor for the observed CYP2C9 enzyme activity variability between 
Koreans and Swedes. Turkish subjects were recruited in one of our sub-studies to investigate 
the effect of Behçet’s disease on CYP2C9 metabolic activity.  
The conclusions of this thesis are: 
• Apart from CYP2C9*2 and *3, other genetic or environmental factors may 
contribute for inter-individuals or inter-ethnic variation in CYP2C9 metabolism. We 
found that IVS8-109A>T does have a lowering effect on losartan metabolism. We 
also found that there are polymorphisms of CYP2C9 haplotypes between the Koreans 
and Swedes.  
• Interestingly, we found that genetics have different levels of impact on the enzyme 
activity of Koreans than on Swedes. Swedes are more affected by CYP2C9 genotype 
(*2 and *3) than Koreans (40% vs 27% predicted impact, respectively). Smoking is 
seen as a predictor in Koreans and the reason is unknown.  
• There was a significant different in CYP2C9 activity between the healthy Turkish 
subjects and the Behçet’s patients. In the Behçet’s patients group, we identified 
genetics, the disease and concomitant drugs as predictors to lower CYP2C9 metabolic 
activity.  
• We found that the inflammatory reaction agents actually cause an inhibition towards 
CYP2C9 regulation after observing that there is no difference in the CYP2C9 allele 
frequencies between the two groups and the drugs used by a majority of the patients 
have no conclusive effect after two weeks. 
• The impact of the common P450 oxidoreductase variant A503V (POR*28) on 
CYP2C9-losartan metabolism was investigated. An interesting link between POR*28 
allele and a 1.4-fold increase of activity in CYP2C9-losartan metabolism in Swedes 
was found. No effect was observed in individuals with POR*28 on the metabolic 
activity of CYP2C9 in Koreans. 
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ERRATA: THIS PAGE LISTS ERRORS FOUND IN THE SUBMITTED VERSION 
OF PAPER I, TOGETHER WITH CORRECTIONS WHERE APPLICABLE. 
Location: Fig 1A, Paper I ; the genotype change and median MR added to SNP 2 and SNP3 
for Swedes and  SNP 1+ 2 + 3 in Koreans 
 
Location: Fig 1B, Paper I; rs number changed for SNP 4 
 
 
